Literature DB >> 20598580

Comparison of wait times and mortality for idiopathic pulmonary fibrosis patients listed for single or bilateral lung transplantation.

Steven D Nathan1, Oksana A Shlobin, Shahzad Ahmad, Nelson A Burton, Scott D Barnett, Erik Edwards.   

Abstract

BACKGROUND: Lung transplantation is the one form of solid-organ transplantation in which there is the option for patients to receive one or two organs. Idiopathic pulmonary fibrosis (IPF) candidates can be accommodated by either procedure but the decision about these two options remains controversial. Therefore, we sought to determine whether IPF patients listed for bilateral lung transplantation only had longer wait times and higher mortality on the waiting list than those listed for single lungs only. Patients with chronic obstructive pulmonary disease (COPD) were also analyzed as a comparison group.
METHODS: This study was a retrospective analysis of the Organ Procurement and Transplantation Network database of patients with IPF and COPD listed for lung transplantation between May 2005 and December 2007. An analysis of wait times and mortality in this era as well as the pre-lung allocation score (pre-LAS) era of 2002 to 2004 was performed.
RESULTS: Of the 1,339 patients with IPF listed for lung transplantation, 31.7% were listed for bilateral lung transplantation only, 41% for single-lung transplantation only and 27.3% for either procedure. Patients listed for the bilateral procedure only were at greater risk of dying on the transplant list (p < 0.003), and were less likely to receive a lung transplant (p < 0.012). No difference in outcomes was seen in the COPD patients. Comparatively, in the pre-LAS era, wait times and mortality on the list for IPF patients were significantly greater for all forms of transplantation.
CONCLUSIONS: There has been a significant improvement in wait times and mortality for IPF patients since the inception of the LAS system. Nonetheless, despite the goal of transplant equity, IPF patients listed for bilateral lung transplantation might have a clinically meaningful increased risk of pre-transplant mortality. The choice of procedures therefore needs to be made with careful consideration of patients' survival both pre- and post-transplantation. Evaluation of transplant outcomes should not only be based on post-transplant survival, but should also account for the impact of the choice of procedure.
Copyright © 2010 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20598580     DOI: 10.1016/j.healun.2010.05.014

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  15 in total

1.  Lung transplant for interstitial lung disease: outcomes for single versus bilateral lung transplantation.

Authors:  Nilto C De Oliveira; Satoru Osaki; James Maloney; Richard D Cornwell; Keith C Meyer
Journal:  Interact Cardiovasc Thorac Surg       Date:  2011-12-16

Review 2.  Autophagy and Obesity-Related Lung Disease.

Authors:  Maria A Pabon; Kevin C Ma; Augustine M K Choi
Journal:  Am J Respir Cell Mol Biol       Date:  2016-05       Impact factor: 6.914

3.  Procedure Preference and Intention-to-Treat Outcomes after Listing for Lung Transplantation among U.S. Adults. A Cohort Study.

Authors:  Michaela R Anderson; Ashley Tabah; Arindam RoyChoudhury; David J Lederer
Journal:  Ann Am Thorac Soc       Date:  2019-02

Review 4.  Lung transplantation for pulmonary sarcoidosis.

Authors:  Keith C Meyer
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

5.  Staging of Bilateral Lung Transplantation for High-Risk Patients With Interstitial Lung Disease: One Lung at a Time.

Authors:  M G Hartwig; A M Ganapathi; A A Osho; S A Hirji; B R Englum; P J Speicher; S M Palmer; R D Davis; L D Snyder
Journal:  Am J Transplant       Date:  2016-07-15       Impact factor: 8.086

Review 6.  Therapeutic update in idiopathic pulmonary fibrosis.

Authors:  Andrew L Chan; Rokhsara Rafii; Samuel Louie; Timothy E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

Review 7.  Advanced therapies for COPD-What's on the horizon? Progress in lung volume reduction and lung transplantation.

Authors:  Michael A Trotter; Peter M Hopkins
Journal:  J Thorac Dis       Date:  2014-11       Impact factor: 2.895

8.  A review of current and novel therapies for idiopathic pulmonary fibrosis.

Authors:  Rokhsara Rafii; Maya M Juarez; Timothy E Albertson; Andrew L Chan
Journal:  J Thorac Dis       Date:  2013-02       Impact factor: 2.895

Review 9.  Idiopathic pulmonary fibrosis: early detection and referral.

Authors:  Justin M Oldham; Imre Noth
Journal:  Respir Med       Date:  2014-04-04       Impact factor: 3.415

10.  Ten-Year Survival in Patients with Idiopathic Pulmonary Fibrosis After Lung Transplantation.

Authors:  Liesbeth ten Klooster; George D Nossent; Johanna M Kwakkel-van Erp; Diana A van Kessel; Erik J Oudijk; Ed A van de Graaf; Bart Luijk; Rogier A Hoek; Bernt van den Blink; Peter Th van Hal; Erik A Verschuuren; Wim van der Bij; Coline H van Moorsel; Jan C Grutters
Journal:  Lung       Date:  2015-09-24       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.